- Home
- KROS
KROS
Keros Therapeutics Inc.
as 05-09-2025 4:00pm EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | $23.14 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.12 - $72.37 | Next Earning Date: | 05-06-2025 |
| Revenue: | $214,713,000 | Revenue Growth: | 91657.70% |
| Revenue Growth (this year): | 91.8% | Revenue Growth (next year): | 54.21% |
Stock Insider Trading Activity of Keros Therapeutics Inc. (KROS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | KROS | 10% Owner | Apr 9 '25 | Buy | $9.40 | 34,925 | $328,127.36 | 3,493,404 |
Latest Keros Therapeutics Inc. News
KROS Breaking Stock News: Dive into KROS Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Keros Therapeutics First Quarter 2025 Earnings: Beats Expectations
Zacks
3 days ago
Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates
GlobeNewswire
3 days ago
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
Zacks
8 days ago
Implied Volatility Surging for Keros Therapeutics Stock Options
TipRanks
a month ago
Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz
MT Newswires
a month ago
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires
a month ago
Update: Keros Therapeutics Shares Rise After Board Initiates Review of Strategic Alternatives
Pharmaceutical Technology
a month ago
Keros Therapeutics considers sale amid investor pressure
Compare KROS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KROS Keros Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.